Corxel raises US$287m in Series D funding to support oral GLP-1 trials for obesity. The funding will accelerate global development for new cardiometabolic disease therapies.
Amount Raised
$287 Million
Round Type
Series D
ShanghaiBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Corxel has raised US$287m in a series D funding round to finance phase 2 studies of its oral GLP-1 receptor agonist for obesity and support planned phase 3 trials. The funding will also help in the development of other clinical-stage assets. The round saw previous backers joined by several new investors. This funding is seen as a significant milestone for the company.
Quick answer
Corxel raised $287 Million in a Series D round, dated January 26, 2026. Investors: Symbiosis, HBM Healthcare Investments, RA Capital Management, Tcgx, SR One, Hengdian Group Capital and RTW Investments. Corxel is based in Shanghai, China.
- How much did Corxel raise?
- Corxel raised $287 Million in a Series D round on January 26, 2026.
- Who invested in Corxel?
- Symbiosis, HBM Healthcare Investments, RA Capital Management, Tcgx, SR One, Hengdian Group Capital and RTW Investments are named as investors in this round.
- What does Corxel do?
- Corxel, previously known as JiXing Pharmaceuticals, focuses on developing innovative therapies for cardiometabolic diseases.
- Where is Corxel based and how big is it?
- Corxel is based in Shanghai, China.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Corxel that raised within 45 days of this round, from Fundz verified event records.
- Combat Medical raised $3.5M (Series A) on March 12, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Polares Medical SA raised $50M (Series C) on March 3, 2026.
- Faeth Therapeutics raised $200M (Post-IPO Equity) on February 18, 2026.
- Aerska raised $39M (Series A) on February 9, 2026.
- Vivere Oncotherapies raised $10M (Funding Round) on January 13, 2026.
Who to call at Corxel, and when
A new round usually means Corxel is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Corxel raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Corxel, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Corxel. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Corxel raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Corxel raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.